Global Breast Cancer Market Report: 2014 Edition


#214866

65pages

Koncept Analytics

$ 800

In Stock

 

Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death in women. Breast cancer knows no boundaries be it age, gender, socioeconomic status or geographic location. The most common risk factors for breast cancer are being female and growing older.

 

In the past few years, the cases of breast cancer have increased tremendously in regions like the US and the Europe. The breast cancer market is driven by various factors like aging population in women, obesity and diabetes, hormonal factors, race and ethnicity and family history. A major trend which will probably remain eternally in the breast cancer treatment industry is the fact that novel and innovative technologies and pharmaceutical molecules are always under development. Challenges associated with breast cancer are like costs of treatment, regulatory measures and adverse effects of the treatment on patients.

 

The market for breast cancer drugs represents an area of potential opportunity in both developed and developing countries. Due to effectiveness and advancements in technology, a large number of companies are focusing to develop innovative breast cancer drugs. Further, the companies are forming alliances and agreements to develop effective treatment methods for breast cancer.

 

The present report provides a comprehensive analysis of the global breast cancer diagnosis and treatment market with focus on regions like the US, India, China and Brazil. Furthermore, market dynamics such as the industry trends and development, the underlying growth drivers and major issues faced by the industry are elicited. On the contention front, the market is personified by the intense competition in terms of research and development of novel therapeutic molecules. The leading players operating in the industry include Hologic, Johnson and Johnson, Siemens AG, Roche and Novartis which are also profiled in this report.

Table of Content

 

1. Market Overview

1.1 Breast Cancer

1.2 Types of Breast Cancer

1.3 Risk Factors

1.4 Symptoms of Breast Cancer

1.5 Diagnosis and Treatment of Breast Cancer

1.5.1 Breast Cancer Screening and Diagnostic Measures

1.5.2 Breast Cancer Treatment

 

2. Breast Cancer Market

2.1 Global Market

Market Value

Market Segments

2.2 Breast Cancer Diagnostics Market

2.2.1 The US

2.2.2 Brazil

2.2.3 India

2.2.4 China

2.3 Breast Cancer Therapeutics Market

2.3.1 Regional Analysis

2.3.2 Metastatic Breast Cancer

The US

Europe

China

 

3. Market Dynamics

3.1 Industry Developments

3.1.1 Diagnostic Tests

3.1.2 New Drugs & Therapies

3.2 Growth Drivers

3.2.1 Increasing Prevalence of Cancer Cases

3.2.2 Increasing Use of Tobacco and Alcohol

3.2.3 Expanding Obese and Diabetes Population

3.2.4 Rising Demand for Better Healthcare Options

3.2.5 Growing Women Population (+45 Years)

3.2.6 Increased Spending on Medicines

3.2.7 Dense Breast Tissue

3.2.8 Race\Ethnicity

3.2.9 Exposure to Oestrogen

3.2.10 Hormonal Factors or HRT (Hormone Replacement Therapy)

3.2.11 Exposure to Radiation

3.3 Challenges

3.3.1 Rising Costs of Treatment

3.3.2 Stringent Regulatory Measures

3.3.3 Adverse Effects of the Treatment

3.3.4 Mounting Price Pressure

 

4. Competitive Landscape

Competitive Overview

Market Share

 

5. Company Profiles

5.1 Hologic, Inc.

5.1.1 Business Overview

5.1.2 Financial Overview

5.1.3 Business Strategies

Focus on Research & Development

Business Expansion via Acquisitions

5.2 Johnson & Johnson

5.2.1 Business Overview

5.2.2 Financial Overview

5.2.3 Business Strategies

Research and Development Activities

Strategic Acquisitions

5.3 F. Hoffmann-La Roche Ltd

5.3.1 Business Overview

5.3.2 Financial Overview

5.3.3 Business Strategies

Accelerating R&D Activities

Building on Strength in Biotechnology

5.4 Novartis

5.4.1 Business Overview

5.4.2 Financial Overview

5.4.3 Business Strategies

Focus on R&D Activities

Business Expansion via Acquisitions

5.5 Siemens AG

5.5.1 Business Overview

5.5.2 Financial Overview

5.5.3 Business Strategies

Optimum Allocation of R&D Resources

Focus on Healthcare Segment

 

Stages of Breast Cancer

New Cases of Breast Cancer and Estimated Deaths in the US (2014E)

The US Tomosynthesis Market Opportunity

NeuVax / E75 (nelipepimut) Estimated Sales – Breast Cancer Market Size Model (2017E-2020E)

The US MBC Market (in US$ Million) 2010-2015E

European MBC Market (in US$ Million) 2010-2015E

Metasite Breast and Menacalc Are Mechanistically Different From Existing Gene-Based Tests

Breast Cancer Drugs & Agents in Clinical Development

Number of Cancer Cases Worldwide (2012)

IARC and WCRF/AICR Evaluations of Breast Cancer Risk Factors

FDA Regulation of Medical Devices

Comparison of Adjuvant Chemotherapy Tests in Breast Cancer

J&J’s R&D Statistics (2012 & 2013)

 

Types of Breast Cancer

Various Biopsy Methods

Global Oncology Spending (2010-2014E)

Global Breast Cancer Market by Segments (2013E)

Global Breast Cancer Predictive Diagnostic and Drug Technologies (2010-2014E)

The US Breast Imaging Systems Market (2010-2014E)

The US Digital Mammography Market (2010-2013)

Brazil’s Breast Cancer Imaging Market (2010-2014E)

India’s Breast Screening Market (2010-2014E)

China’s Breast Screening Market (2010-2014E)

Global Breast Cancer Therapeutics Market (2010-2014E)

Breast Cancer Therapeutics Market by Region

The US Metastatic Breast Cancer Market Revenues (2010-2014E)

Chinese Metastatic Breast Cancer Market Revenues (2010-2014E)

Breast Cancer Drug Breakdown in China (2013E)

Different Types of Cancer Worldwide (2012)

Increasing Prevalence of Diabetes by Region (2000-2030E)

Global Female Population, +45 Years (2008-2014E)

Global Spending on Medicines (2007-2017E)

New Female Breast Cancer Cases and Deaths by Age, US, (2013)

Global Oncology Pharmaceuticals - Market Share (2013E)

Global Breast Cancer Diagnostics – Market Share (2013E)

Hologic’s Revenue Share by Business Segment (2013)

Hologic’s Revenues (2009-2013)

Johnson & Johnson’s Revenues (2009-2013)

F. Hoffmann-La Roche - Business Segments (2013)

Roche Revenues (2009-2013)

Novartis Business Segments (2013)

Novartis Revenues (2009-2013)

Siemens AG’s Revenue by Business Segments (2013)

Siemens AG’s Revenues & Net Income (2009-2012)